Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 13,466 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Neoplasms, Ovarian
Interventions: SB-485232 (interleukin 18), pegylated liposomal doxorubicin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Stanford, California • Miami, Florida • Philadelphia, Pennsylvania

Conditions: Ovarian Cancer, Non Small Cell Lung Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Cancer of Head and Neck
Interventions: LY2523355, pegfilgrastim; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 18
States / cities: Jonesboro, Arkansas • Jacksonville, Florida • Macon, Georgia + 15 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state), Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Non Small Cell Lung Cancer (NSCLC), Thyroid Cancer, Melanoma, Sarcoma, Solid Tumors
Interventions: Enapotamab vedotin (HuMax-AXL-ADC); Biological
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 20
States / cities: Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 16 more

Conditions: Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome
Interventions: yttrium Y 90-edotreotide; Radiation
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Cardiovascular Diseases, Diabetes
Interventions: SGLT2 inhibitor, GLP-1 RA, Education-First; Drug · Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 27 Years to 79 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes, Pre Diabetes
Interventions: dance, diabetes education; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Mirvetuximab soravtansine, Carboplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 35
States / cities: Tucson, Arizona • Fresno, California • Fullerton, California + 30 more

Conditions: Pituitary Adenoma, Cushing Disease
Interventions: Contrast enhanced pituitary magnetic resonance imaging (MRI), Contrast enhanced ultrasound, Non-Contrast Ultrasound; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: Not listed
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetes Mellitus
Interventions: Pharmacist Management, Usual care; Other
Lead sponsor: Advantage Health Physician Network; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Diabetic Foot Ulcer, Diabetes Mellitus, Foot Ulcer, Foot Ulcer, Diabetic, Ulcer, Ulcer Foot, Ulcer, Leg, Ankle Ulcer
Interventions: Total Contact Soft Cast, Cam Boot; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 1 Diabetes Mellitus
Interventions: Observation During Exercise and Stress; Other
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Santa Barbara, California • Rochester, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: Weekly Automated Health Coaching, Weekly Human Health Coaching, Adapted Reward Level, Fixed Gamified Reward Level; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pancreatic Neoplasms
Interventions: GTX (gemcitabine, docetaxel and capecitabine), stereotactic body radiation therapy; Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Diabetes
Interventions: Wosulin R, Actrapid; Biological
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Loss of Appetite, Fatigue, Cachexia
Interventions: ponsegromab, Placebo for ponsegromab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 19
States / cities: Conway, Arkansas • Little Rock, Arkansas • North Little Rock, Arkansas + 14 more

Conditions: Type 1 Diabetes
Interventions: benfotiamine, α-lipoic acid; Dietary Supplement
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Obesity, Overweight, Type 2 Diabetes
Interventions: LY3549492, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 38
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Greenbrae, California + 33 more

Conditions: Diabetes Mellitus, Type II
Interventions: Metformin, Rosiglitazone, Lovaza; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 27
States / cities: Birmingham, Alabama • Huntsville, Alabama • Anaheim, California + 24 more

Conditions: Type 2 Diabetes
Interventions: dapagliflozin, Placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 20 Years to 80 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Type 2 Diabetes Mellitus
Interventions: Proteus Sustained Behavior Change system, Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors); Device · Drug
Lead sponsor: Proteus Digital Health, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Chicago, Illinois • Boston, Massachusetts

Conditions: Obstructive Jaundice, Pancreatic Cancer
Interventions: Stent Dysfunction, Complications; Procedure
Lead sponsor: AdventHealth; Other
Eligibility: 19 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Diabetes Mellitus
Interventions: SDH Tool; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: Not listed
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Diabetes Remote Intervention to improVe Use of Evidence-based Medications

Dance and Diabetes/Prediabetes Self-Management

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors

Pharmacists Management of Diabetes

Total Contact Soft Cast in Diabetic Foot Ulcers

Impact of Non-glucose Signals on Glycemic Control in Patients With Type 1 Diabetes

GODART Pilot and Feasibility

Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery

Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects.

Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

Reactive Oxygen Species in the Pathogenesis of Diabetic Complications

A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM

Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus

An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin

Proteus Sustained Behavior Change Study

Trial Comparing Metal Versus Plastic Stents for Preoperative Biliary Decompression

ASCEND: ApproacheS to CHC ImplEmeNtation of SDH Data Collection and Action